An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands

Myelodysplastic Syndromes Clinical Trial

— OCEAN  

Official title:

A Non-interventional Observational Post Authorization Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands (OCEAN)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02891551
• Other study ID #: NIPMS-VZ-NL-001
• Status: Completed
• Start date: May 1, 2012
• Est. completion date: December 30, 2018

Study information

• Verified date: July 2019
• Source: Celgene
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study design is a prospective, non-interventional, observational single arm study.

A minimum of 150 patients will be recruited from approximately 30 haematology/oncology sites in the Netherlands. In all cases, the decision to treat the patient with azacitidine was already made prior to the decision to enter the subject into the study.

Recruitment will continue until end of June 2015, provided a minimum of 150 patients have been included in the study. When this date is reached, all patients on azacitidine will continue to be followed until the last patient enrolled has been followed for 12 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 209
• Est. completion date: December 30, 2018
• Est. primary completion date: June 30, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients over 18 years of age who understand and voluntarily sign an informed consent form.

• Patients who are treated with azacitidine in accordance with registered indication and clinical practice.

Exclusion Criteria:

• Refusal to participate in the study.

• Participation in an interventional clinical study.

• Patients previously treated with azacitidine except when given as induction therapy for a maximum of three courses.

• Women who are pregnant or breast-feeding.

• Hypersensitivity to the active substance or to any of the excipients.

• Advanced malignant hepatic tumors.

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Leukemia, Myelomonocytic, Chronic
• Myelodysplastic Syndromes
• Preleukemia

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Celgene

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events (AEs)	Adverse events will be classified using the Medical Drug Regulatory Activities (MedDRA) classification system. The severity of the toxicities will be graded according to the NCI CTCAE VERSION 4.03 whenever possible	Up to approximately 4 years
Secondary	Fact-Anemia Quality of life questionnaire	The Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire was used to assess health-related quality of life (HRQoL). In addition to general HRQoL, the FACT-An measures the impact of fatigue and other anemia-related symptoms on patient functioning.	Up to approximately 4 years
Secondary	Percentage of patients with a Haematological Response in daily clinical practice using the International Work Group Criteria in Myelodysplastic Syndrome Assessed by the Investigator	Hematologic Response according to the 2000 International Working Group (IWG) response criteria for Myelodysplastic Syndrome (MDS)	Up to approximately 4 years
Secondary	Percentage of patients with a Hematologic Improvement Using International Working Group (IWG Criteria for Hematologic Improvement Cheson 2000) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by the investigator in daily clinical practice	Overall hematological improvement (HI) was defined as any type (major or minor) of improvement of HI-E, HI-P, or HI-N. Criteria: Pretreatment=hemoglobin <100g/L or RBC transfusion-dependent, platelet count <100x10^9/L or platelet transfusion dependent, absolute neutrophil count <1.5x10^9/L. Sponsor's determination was derived using clinically relevant data.; Denominator for progression/relapse after HI included participants who had achieved HI.	Up to approximately 4 years
Secondary	Time to treatment Failure daily clinical practice	Time to Treatment Failure is defined as the time from randomization to treatment discontinuation for any reason, including disease progression, treatment toxicity, patient preference, or death.	Up to approximately 4 years
Secondary	Overall Survival in daily clinical practice	Overall survival (OS) was assessed using the time between randomization and the date of death	Up to approximately 4 years